Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients

Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchini, J.F.M., Pinto, M.R., Novaes, G.C., Badran, A.V., Pavão, R.B., Figueiredo, G.L., Lago, I.M., Lima-Filho, M.O., Lemos, D.C., Tonani, M., Antloga, C.M., Oliveira, L., Lorenzi, J.C., Marin-Neto, J.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2017
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264542/
https://www.ncbi.nlm.nih.gov/pubmed/28076455
http://dx.doi.org/10.1590/1414-431X20165660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264542/
https://www.ncbi.nlm.nih.gov/pubmed/28076455
http://dx.doi.org/10.1590/1414-431X20165660

Ejemplares similares